Table of Contents page: European Journal of Cancer

Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Editorial comment

The use of gene expression profiling and mutation analysis increases the cost of care for patients with carcinoma of unknown primary; does it also improve survival?

Vinay Prasad,
Andrew Oseran,
Farhad Fakhrejahani

Published online: November 19, 2015

p159-162

Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials

J.R. Kroep,
A. Charehbili,
R.E. Coleman,
...
G.J. Liefers,
J.W.R. Nortier,
N. Kohno

Published online: December 23, 2015

p57-63

Open Access

Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a ‘chemosensitive’ relapse: A single-arm phase II study (EORTC-08061)

Fatma Abdelraouf,
Egbert Smit,
Baktiar Hasan,
...
Veerle F. Surmont,
Paul Baas,
Mary O'Brien

Published online: December 21, 2015

p35-39

Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities

Barbara Bournet,
Camille Buscail,
Fabrice Muscari,
Pierre Cordelier,
Louis Buscail

Published online: December 28, 2015

p75-83

Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study.

Hiroshi Imaoka,
Tadayuki Kou,
Masao Tanaka,
...
Shujiro Yazumi,
Yasuhiro Shimizu,
Kenji Yamao

Published online: December 29, 2015

p96-103

Predicting survival of men with recurrent prostate cancer after radical prostatectomy

Paolo Dell'Oglio,
Nazareno Suardi,
Stephen A. Boorjian,
...
Francesco Montorsi,
R. Jeffrey Karnes,
Alberto Briganti

Published online: December 18, 2015

p27-34

Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?

Damien Pouessel,
Sylvie Chevret,
Frédéric Rolland,
...
François Audenet,
Thomas Grellety,
Stéphane Culine

Published online: December 24, 2015

p69-74

Single-nucleotide polymorphism in the 5-α-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors

Hink Boer,
Nico-Derk L. Westerink,
Renske Altena,
...
Andries J. Smit,
Coby Meijer,
Jourik A. Gietema

Published online: January 02, 2016

p104-111

Gene expression test for the non-invasive diagnosis of bladder cancer: A prospective, blinded, international and multicenter validation study

Maria J. Ribal,
Lourdes Mengual,
Juan J. Lozano,
...
Joerg Schmidbauer,
Pedro L. Fernández,
Antonio Alcaraz

Published online: January 04, 2016

p131-138

Impact of surgical staging on prognosis in patients with borderline ovarian tumours: A meta-analysis

Seung-Hyuk Shim,
Soo-Nyung Kim,
Phill-Seung Jung,
Meari Dong,
Jung Eun Kim,
Sun Joo Lee

Published online: December 28, 2015

p84-95

Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients

Esther M. van Wezel,
Boris Decarolis,
Janine Stutterheim,
...
C. Ellen van der Schoot,
Barbara Hero,
Godelieve A.M. Tytgat

Published online: January 12, 2016

p149-158

A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Ian W. Flinn,
Nancy L. Bartlett,
Kristie A. Blum,
...
Fred Zheng,
Jeffrey M. Skolnik,
Jonathan W. Friedberg

Published online: December 17, 2015

p11-17

Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias

Eline M.P. Cremers,
Theresia M. Westers,
Canan Alhan,
...
Pino J. Poddighe,
Gert J. Ossenkoppele,
Arjan A. van de Loosdrecht

Published online: December 22, 2015

p49-56

Endocrine disorders among long-term survivors of childhood head and neck rhabdomyosarcoma

S.C. Clement,
R.A. Schoot,
O. Slater,
...
H.N. Caron,
H.M. van Santen,
J.H.M. Merks

Published online: December 17, 2015

p1-10

Perioperative treatment and radical cystectomy for bladder cancer – a population based trend analysis of 10,338 patients in the Netherlands

Tom J.N. Hermans,
Elisabeth E. Fransen van de Putte,
Simon Horenblas,
...
Laurens V. Beerepoot,
Rob H. Verhoeven,
Bas W.G. van Rhijn

Published online: December 17, 2015

p18-26

Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time

Carin A.T.C. Lunenburg,
Linda M. Henricks,
Henk-Jan Guchelaar,
...
Maarten J. Deenen,
Jan H.M. Schellens,
Hans Gelderblom

Published online: December 21, 2015

p40-48

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

J.M. Michot,
C. Bigenwald,
S. Champiat,
...
J.C. Soria,
A. Marabelle,
O. Lambotte

Published online: January 05, 2016

p139-148

Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care

Didier Meulendijks,
J.G. Coen van Hasselt,
Alwin D.R. Huitema,
...
Jos H. Beijnen,
Annemieke Cats,
Jan H.M. Schellens

Published online: January 04, 2016

p120-130

Rationale for anti-CD137 cancer immunotherapy

Amani Makkouk,
Cariad Chester,
Holbrook E. Kohrt

Published online: January 02, 2016

p112-119

Transition guidelines: An important step in the future care for childhood cancer survivors. A comprehensive definition as groundwork

R.L. Mulder,
H.J.H. van der Pal,
G.A. Levitt,
...
R. Windsor,
G. Michel,
E. Frey

Published online: December 28, 2015

p64-68

Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors?

Matteo Lambertini,
Paola Anserini,
Lucia Del Mastro

Published online: December 17, 2015

p163-164

Response to ‘Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors?’

Oranite Goldrat,
Isabelle Demeestere,
Hatem A. Azim Jr

Published online: December 08, 2015

p165-166

Small data sets to develop and validate prognostic models are problematic

Gary S. Collins,
Yannick Le Manach

Published online: December 16, 2015

p167-168

Small datasets to develop and validate prognostic models may be a necessary evil to study rare tumours

Sara Valpione,
Simone Mocellin,
Luca Giovanni Campana

Published online: December 28, 2015

p169-171

Two cases of immune thrombocytopenia associated with pembrolizumab

Audrey Le Roy,
Emmanuelle Kempf,
Felix Ackermann,
...
Christine Mateus,
Jean-Marie Michot,
Olivier Lambotte

Published online: December 10, 2015

p172-174

Popular Articles

February 2016

Editorial comment

Breast cancer

Lung cancer

Gastrointestinal oncology

Urologic oncology

Gynecologic oncology

Sarcoma

Hematology

Pediatric oncology

Epidemiology and prevention

Basic science and preclinical research

Tumour immunology and immunotherapy

Treatment side effects

Special series: Immunotherapy

Cancer survivorship and continued care

Correspondence